Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Biomarker discovery Driving technologies" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Biomarker discovery Driving technologies for you to read. Along with our medical data and news we also list Biomarker discovery Driving technologies Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biomarker discovery Driving technologies Companies for you to search.
The Manchester, UK-based Stoller Biomarker Discovery Centre is a major step forward in precision medicine and making 'industrial' proteomics a reality
A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis. The researchers have identified new biomarkers for Tuberculosis (TB) which have shown for the first time why immunity from the widely used Bacillus Calmette-Guérin (BCG) vaccine is so variable. The biomarkers will also provide valuable clues ...
Blueprint Bio Inc. (personalized medicine using biomarker drug discovery) secured $7.5mm in its Series A financing round from Forentis Partners LLC. The company will use the proceeds to further develop its intellectual property and support additional drug discoveries.
Biomarkers of Cancer Larry H. Bernstein, MD, FCAP, Curator LPBI Biomarker Discovery Gets a Fix on Cancer GEN Feb 1, 2016 (Vol. 36, No. 3) http://www.genengnews.com/gen-articles/biomarker-discovery-gets-a-fix-on-cancer/5674/ Just Because Cancer Is a Moving Target—Emerging Here, Eluding Treatment There—Doesn’t Mean It Can’t Be Tracked Kathy Liszewsky http://www.genengnews.com/Med...
Epistem plc, the UK biotechnology and personalised medicine company today announced a collaboration with sanofi-aventis U.S. Inc. relating to the use of Epistem's proprietary biomarker gene expression profiling and immunohistochemistry technologies. Under the terms of the agreement sanofi-aventis has entered into a 3 year collaboration with Epistem to provide discovery through to clinical biomarke...
Tuesday, May 10th 2016 at 1:32pm UTC MADISON, Wis.–(BUSINESS WIRE)– Stemina Biomarker Discovery Inc. today announced it has rebranded its diagnostics business to more accurately represent its focus on neurological disorders. NeuroPointDX is transforming diagnosis and allowing more precise treatment of neurological disorders based on the patient’s metabolism. The company’s proprieta...
Blueprint Bio Inc. (personalized medicine using biomarker drug discovery) secured $7.5mm in early-stage funding from Forentis Partners LLC. The company will use the proceeds to further develop its intellectual property and support additional drug discoveries.
A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis.
British company C4X Discovery has acquired a suite of advanced drug-discovery technologies from MolPlex…
Robert Little, the Chief Business Officer of Denovo Biomarkers reveals to Fintan Walton the use of its industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples.
Horizons of drug discovery Larry H. Bernstein, MD., FCAP, Curator LPBI Phenotypic and Biomarker-based Drug Discovery NY Acad Sci. http://www.nyas.org/Publications/Ebriefings/Detail.aspx Organizers: Michael Foley (Tri-Institutional Therapeutics Discovery Institute), Ralph Garippa (Memorial Sloan-Kettering Cancer Center), David Mark (F. Hoffmann-La Roche), Lorenz Mayr (Astra Zeneca), Joh...
In the setting of inflammatory diseases, metabolic profiling has potential applications in diagnosis, monitoring and defining disease pathogenesis. This Review focuses on metabolomic studies in rheumatic diseases, including discussion of state-of-the-art technologies, recent insights into disease mechanisms and treatment targets, and the feasibility of metabolomics for biomarker discovery.
Differentiated technologies buoyed by the recent $600m conjugation deal with Roche is driving Catalent’s biologics business, the firm told Biopharma-Reporter at BIO.
A biomarker helps physicians predict, diagnose or monitor disease, because the biomarker corresponds to the presence or risk of disease,...
(University of Pennsylvania) The University of Pennsylvania has co-founded and structured BluePen Biomarkers in collaboration with BluePrint Bio, Inc. and Emerald Logic, Inc. to conduct biomarker research and identification. BluePen is creating a comprehensive biomarker measurement and discovery pipeline for the acceleration of personalized medicine.
Berlin, Germany, July 10, 2016 --(PR.com)-- Richard E. Buller, Vice President of Oncology, Clinical Development & Head of Global Product Development at Pfizer will give a keynote presentation on, "Feedback Loops Between Biomarkers and Targeted Agents in Clinical Trials and Beyond: Lessons from Anaplastic Lymphoma Kinase (ALK+) Driven Non-Small Cell Lung Cancer (NSCLC)" at GTCbioR...
(American Friends of Tel Aviv University) A new discovery by Tel Aviv University researchers takes the medical community a leap forward in the process of effectively screening and diagnosing Alzheimer's disease. The study proposes a new biomarker for cognitive aging and Alzheimer's disease, the levels of which can be easily monitored in routine blood tests.
Glycosylation is one of the most prevalent co- and post-translational modifications of human proteins and is known to affect the protein properties. Glycosylation is known to be involved in many different diseases. The sialic acids at the end of the glycan chain serve as a binding site for toxins, pathogens and human lectins in a linkage-specific manner having great biomarker potential. During th...
LEXINGTON, Mass., July 18, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, has signed a multi-year agreement to provide T2 Biosystems’ T2 Magnetic Resonance technology platform, or T2MR®, for Bayer’s research and development efforts in blood coagulation disorders. This collaboration will develop to...
Driving is a very complex process. Today, almost half of all drivers on the roadways are over the age of 65. With the decline of cognitive processes in older adults such as Alzheimer's disease, there is heightened concern for public safety and unsafe driving in this population. Understanding the cognitive factors that inhibit effective driving as well as recognizing older adults who may be at risk...
Following its acquisition of colorectal cancer testing company Enterix Inc. earlier this year, Quest Diagnostics Inc. has spun off that company's biomarker business into a new firm, Clinical Genomics Technologies Pty. Ltd. Quest holds a 19.9% equity stake in the spin-off, according to regulatory filings.
(Florida Atlantic University) Driving is a very complex process. Today, almost half of all drivers on the roadways are over the age of 65. With the decline of cognitive processes in older adults such as Alzheimer's disease, there is heightened concern for public safety and unsafe driving in this population. Understanding the cognitive factors that inhibit effective driving as well as recognizing o...
Portland, OR, June 19, 2016 --(PR.com)-- According to a new report titled "Biomarkers Market (Diagnostic Applications in Risk Assessment, Molecular Diagnostics, Disease Diagnosis, Drug Discovery & Development, Drug Formulation, Forensic Applications and Others) - Global Industry Analysis, Emerging Technologies, Competitive Intelligence, Growth Trends, Size, Share, Opportunities and Forec...
Toronto, ON (PRWEB) March 17, 2016 Crawford Technologies announced today that its new Voiceye solution â allowing visually-impaired customers to read printed pages - has been featured on the Discoveryâs Channelâs NewsWatch program. NewsWatch is a 30-minute segment airing weekly in more than 2...